The Oncology Institute, Inc.
$6.20+$0.04 (+0.6%)
Last close · Data as of Aug 11, 2026
- Market cap
- $473.9M
- P/E
- -7.8x
- EV / EBITDA
- -12.8x
- Revenue
- $502.7M
- Net margin
- -12.1%
- ROCE
- -38.5%
Price chart
Technical chartScreen technicals →Hidden because the last close is more than three trading days older than the latest prices of its class.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 11 Aug 2026 close.
- 1M
- Stale
- 3M
- Stale
- 6M
- Stale
- 1Y
- Stale
- 5Y
- Stale
- Hidden because the last close is more than three trading days older than the latest prices of its class.
52-week range
Day change +$0.04 (+0.6%) from $6.16 to $6.20 · Last close Aug 11, 2026
Best weekday to invest, historically
The same weekly amount in TOI, bought on each weekday since 2021.
News & filings
What The Oncology Institute filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths
No strength stands out for this company on the data on file.
- Prices are as of 11 Aug 2026; price-based points are paused until newer prices arrive.
- The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
Prices to the 11 Aug 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
Read moreShow less
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
- Sector
- Healthcare
- Shares outstanding
- 98.9M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $473.9M
- P/E
- -7.8x
- P/B
- -30.1x
- EV / EBITDA
- -12.8x
- EV / Sales
- 1.1x
- P/S
- 0.9x
- 52-week high
- $6.41
- 52-week low
- $2.38
Profitability
- Operating margin
- -7.2%
- Net margin
- -12.1%
- EBITDA margin
- -8.5%
- ROE
- 385.5%
- ROCE
- -38.5%
- ROIC
- -71.8%
- ROA
- -36.8%
- Asset turnover
- 3.05
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $502.7M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 27.8%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 25.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -6.3%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$27.8M
Solvency
- Current ratio
- 1.59
- Debt / Equity
- -6.60
- Debt / Assets
- 0.63
- CFO / Net profit
- 0.41
- Cash / Market cap
- 7.1%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $502.7M |
| Cost of revenue | $426.3M |
| Gross profit | $76.4M |
| Operating expenses | $112.5M |
| Selling, general and administrative | $105.6M |
| Operating income | -$36.1M |
| Interest and other | -$24.7M |
| Pretax income | -$60.7M |
| Tax and other | -$130.0k |
| Net income | -$60.6M |
Revenue and net profit
Revenue grew 27.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $252.5M | $152.0k |
| FY2023 | $324.2M | -$83.1M |
| FY2024 | $393.4M | -$64.7M |
| FY2025 | $502.7M | -$60.6M |
Cash flows
FY2025: -$24.6M from operations, -$27.8M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$61.8M | -$67.3M |
| FY2023 | -$36.3M | -$40.9M |
| FY2024 | -$26.5M | -$30.3M |
| FY2025 | -$24.6M | -$27.8M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $502.7M+27.8%1Y
- EBITDA
- -$42.5M
- Net profit
- -$60.6M
- Cash from operations
- -$24.6M
- Free cash flow
- -$27.8M
- Revenue CAGR, 3Y
- 25.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $502.7M | -$42.5M | -$60.6M | -$27.8M | 385.5% | +27.8% | -6.3% |
Monthly returns
Month-by-month returns of TOI across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $164.7M |
| Current assets | $112.8M |
| Non-current assets | $51.9M |
| Liabilities | $180.4M |
| Current liabilities | $71.0M |
| Non-current liabilities | $109.4M |
| Equity | -$15.7M |
| Paid-in capital | $256.7M |
| Retained earnings | -$271.4M |
| Treasury stock | $1.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; TOI highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| The Oncology Institute, Inc.TOIthis company | $473.9M | -7.8x | -30.1x | 385.5% | -12.8x |
| AngioDynamics, Inc.ANGO | $497.1M | -14.6x | 2.7x | -18.6% | 256.3x |
| Standard BioTools Inc.LAB | $495.8M | -6.6x | 1.2x | -17.7% | -4.7x |
| Evolent Health, Inc.EVH | $492.7M | -0.9x | 1.2x | -128.7% | -3.7x |
| Prothena Corporation plcPRTA | $484.3M | -2.0x | 1.7x | -87.0% | -1.0x |
| CTEVCTEV | $470.0M | — | — | 163.5% | 10.8x |
| OrthoPediatrics Corp.KIDS | $464.9M | -11.7x | 1.3x | -11.4% | -69.2x |
| Weave Communications, Inc.WEAV | $459.1M | -16.4x | 5.6x | -34.1% | -42.3x |
| Editas Medicine, Inc.EDIT | $458.9M | -2.9x | 16.8x | -586.6% | -2.2x |
| Peer median | — | -6.6x | 1.7x | -26.3% | -3.0x |
Year-to-date ROI
TOI since 1 January, against earlier years.
Historical volatility
TOI's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -28.5% |
| FY2023 | -18.6% |
| FY2024 | -15.3% |
| FY2025 | -7.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $502.7M |
| Cost of revenueCost Of Revenue | $426.3M |
| Gross profitGross Profit | $76.4M |
| Operating expensesOperating Expense | $112.5M |
| Selling, general and administrativeSelling General And Administration | $105.6M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $6.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $6.9M |
| Total expensesTotal Expenses | $538.8M |
| Operating incomeOperating Income | -$36.1M |
| Interest and other | |
| Pretax incomePretax Income | -$60.7M |
| TaxTax Provision | -$130.0k |
| Net incomeNet Income | -$60.6M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $164.7M |
| Current assetsCurrent Assets | $112.8M |
| Non-current assetsTotal Non Current Assets | $51.9M |
| LiabilitiesTotal Liabilities Net Minority Interest | $180.4M |
| Current liabilitiesCurrent Liabilities | $71.0M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $109.4M |
| EquityTotal Equity Gross Minority Interest | -$15.7M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$24.6M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$24.6M |
| Net income, continuing operationsNet Income From Continuing Operations | -$60.6M |
| Depreciation and amortisationDepreciation And Amortization | $6.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $6.9M |
| Amortization of securitiesAmortization Of Securities | $0.00 |
| Stock-based compensationStock Based Compensation | $4.5M |
| Deferred taxDeferred Tax | -$30.0k |
| Deferred income taxDeferred Income Tax | -$30.0k |
| Operating gains and lossesOperating Gains Losses | $14.8M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $14.8M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $0.00 |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | $0.00 |
| Asset impairmentAsset Impairment Charge | — |
| Change in working capitalChange In Working Capital | $1.3M |
| Other non-cash itemsOther Non Cash Items | $8.4M |
| Investing cash flowInvesting Cash Flow | -$3.1M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$3.1M |
| Capital expenditureCapital Expenditure | -$3.2M |
| Purchase of PP&EPurchase Of PPE | -$3.2M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$3.2M |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | — |
| Sale of investmentsSale Of Investment | $0.00 |
| Net investment purchases and salesNet Investment Purchase And Sale | $0.00 |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | $130.0k |
| Financing cash flowFinancing Cash Flow | $11.6M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $11.6M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$20.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$20.0M |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$20.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$20.0M |
| Shares issuedIssuance Of Capital Stock | $29.2M |
| Common stock issuedCommon Stock Issuance | $29.2M |
| Net common stock issuedNet Common Stock Issuance | $29.2M |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Stock options exercisedProceeds From Stock Option Exercised | $3.4M |
| Preferred stock issuancePreferred Stock Issuance | — |
| Net preferred stock issuanceNet Preferred Stock Issuance | — |
| Other financing chargesNet Other Financing Charges | -$1.0M |
| Change in cashChanges In Cash | -$16.1M |
| Cash at the start of the yearBeginning Cash Position | $49.7M |
| Cash at the end of the yearEnd Cash Position | $33.6M |
| Free cash flowFree Cash Flow | -$27.8M |
| Supplemental |
Learn while you research
Academy chapters picked for The Oncology Institute, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing28% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read